Spotlight on Polyethylene Glycol-Liposomal Doxorubicin in Solid and Hematological Malignancies and AIDS-Related Kaposi??s Sarcoma*

Sharpe, Miriam; Easthope, Stephanie E.; Keating, Gillian M.; Lamb, Harriet M.

doi:10.2165/00024669-200302010-00007

Cited by 28 publications

(35 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sterically stabilized lipospomal variants of doxorubicin and cisplatin are commercially available and have been shown to exhibit higher therapeutic efficacy or at least better tolerability than the free drugs. Both agents have so far been successfully tested against various solid tumors including breast cancer (Rivera 2003, O'Brien 2008), Kaposi's sarcoma (Coukell & Spencer 1997, Sharpe et al 2002, non-squamous non-small-cell lung cancer (Mylonakis et al 2009, Stathopoulos et al 2011, and pancreatic cancer (Stathopoulos et al 2006), among others. Recently, we have demonstrated an extraordinary uptake phenomenon of liposomes, specifically in adrenocortical tumor cells (Hantel et al 2010(Hantel et al , 2012.…”

Section: Introductionmentioning

confidence: 99%

Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model

Hantel¹,

Jung²,

Mussack³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

Owing to high relapse rates and early metastatic spread, prognosis in adrenocortical carcinoma (ACC) patients remains poor, highlighting the importance of developing new treatment alternatives for them. Recently, polychemotherapy regimens including etoposide, doxorubicin, and cisplatin together with mitotane (EDP-M) have been defined as the standard treatment for late-stage disease patients. Nevertheless, the administration of conventional cytostatic drugs is associated with severe and dose-limiting side effects. In an attempt to optimize existing clinical treatment regimens, in this study, we investigated the therapeutic efficacy of EDP-M in comparison with that of a paclitaxel-modified scheme (paclitaxel, doxorubicin, cisplatin plus mitotane (PDP-M)) in preclinical in vitro and in vivo models. In addition, based on an extraordinary uptake phenomenon of liposomes in ACC cells, we further evaluated liposomal variants of these protocols (etoposide, liposomal doxorubicin, liposomal cisplatin plus mitotane (LEDP-M) and nab-paclitaxel, liposomal doxorubicin, liposomal cisplatin plus mitotane (LPDP-M)). In vitro, PDP-M was more potent in the induction of apoptosis and inhibition of cell viability as well as cell proliferation than EDP-M. Following the administration of a single therapeutic cycle, we further demonstrated that LEDP-M and LPDP-M exerted significant antitumoral effects in vivo, which were not as evident upon EDP-M and PDP-M treatments. These results were confirmed in a long-term experiment, in which the highest and sustained antitumoral effects were observed for LEDP-M. In summary, liposomal cytostatic substances could represent a promising option that deserves testing in appropriate clinical protocols for the treatment of ACC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model

Hantel¹,

Jung²,

Mussack³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…It accounts for 0.4 % of all soft tissue tumor and is mostly diagnosed in young or middle aged adults. It is considered a low or intermediate grade malignancy but has significant recurrent or metastatic potential with low mortality [3]. Most cases develop in lymph node especially in cervical, axillary and mediastinal region but 30 % cases develop in extra nodal sites which include head and neck ( palate, tonsil, pharynx, thyroid), breast, liver, spleen, pancreas and bowel [4][5][6].…”

Section: Discussionmentioning

confidence: 99%

Follicular Dendritic Cell Sarcoma Mediastinum - a case report

Bushan¹

2014

Indian J Surg Oncol

View full text Add to dashboard Cite

Follicular dendritic cell tumor (FDCT) are extremely rare difficult to diagnose category tumors.There has been a considerable controversy in medical community regarding precise classification and optimal management of this tumor with some treating it as a form of non Hodgkins lymphoma and some as soft tissue sarcomas.The number of published cases are still low and documentation too heterogenous to give statistically ified therapeutic recommendation of these tumors.This case report aims to highlight various aspects of diagnosing and treating this rare entity.

show abstract

“…These are mainly low molecular weight drugs or therapeutic proteins that are chemically linked to water-soluble polymers to increase drug solubility, drug stability, or enable site-specific transport of drugs to target tissues affected by disease. Separately, PEGcoated liposomes carrying chemotherapeutic drugs have been approved for clinical use [112,113]. They served as first examples of nanoscale materials that found practical application in medicine, called collectively nanomedicines.…”

Section: Nanocarriers For Cns Drug Deliverymentioning

confidence: 99%

Nanomedicine in the diagnosis and therapy of neurodegenerative disorders

Kabanov

Gendelman

2007

Progress in Polymer Science

242

138

View full text Add to dashboard Cite

Neurodegenerative and infectious disorders including Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, and stroke are rapidly increasing as population's age. Alzheimer's disease alone currently affects 4.5 million Americans, and more than $100 billion is spent per year on medical and institutional care for affected people. Such numbers will double in the ensuing decades. Currently disease diagnosis for all disorders is made, in large measure, on clinical grounds as laboratory and neuroimaging tests confirm what is seen by more routine examination. Achieving early diagnosis would enable improved disease outcomes. Drugs, vaccines or regenerative proteins present "real" possibilities for positively affecting disease outcomes, but are limited in that their entry into the brain is commonly restricted across the blood-brain barrier. This review highlights how these obstacles can be overcome by polymer science and nanotechnology. Such approaches may improve diagnostic and therapeutic outcomes. New developments in polymer science coupled with cell-based delivery strategies support the notion that diseases that now have limited therapeutic options can show improved outcomes by advances in nanomedicine.

show abstract

Spotlight on Polyethylene Glycol-Liposomal Doxorubicin in Solid and Hematological Malignancies and AIDS-Related Kaposi??s Sarcoma*

Cited by 28 publications

References 28 publications

Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model

Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model

Follicular Dendritic Cell Sarcoma Mediastinum - a case report

Nanomedicine in the diagnosis and therapy of neurodegenerative disorders

Contact Info

Product

Resources

About